IP Library Granted Patent US 10,301,319
Granted Patent B2
US 10,301,319 · App. 16/135,287 · Granted May 28, 2019

Thailanstatin analogs

Inventors: Vasu Jammalamadaka (Dublin, CA); Sanjeev Satyal (San Carlos, CA); Hoyoung Huh (Portola Valley, CA)
Assignee: pH Pharma Co., Ltd.
C07D493/10A61K45/06A61K47/6803A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,301,319
App. No.
16/135,287
Granted
May 28, 2019
Kind
B2
Abstract

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

Claims (21)

1. A compound of Formula (I):

wherein:

R is selected from the group consisting of: —(CH 2 ) n —R 1 ; 5 to 6 membered heteroaryl, where heteroaryl is optionally substituted with one or more of halogen, —CF 3 , —C 1-6 alkyl, and —O—C 1-6 alkyl;

—C(R 2 )═N—R 3 ; —CH(CF 3 )NH(CH 2 ) m CH 3 ; —C(R a R b )NH(CH 2 ) m CH 3 ;

—C(halogen)═CH(CH 2 ) m CH 3 ; —SO 2 —NH(CH 2 ) m CH 3 ; —O(CO)-aryl; —O(CO)-heteroaryl;

—NR a R b ; and —NH-heteroaryl;

wherein R 1 is —O—CR a R b (CH 2 ) m CH 3 or —N—CR a R b (CH 2 ) m CH 3 ;

wherein R a and R b , together with the atoms to which they are joined, form a C 3-10 heterocyclyl ring;

R 2 is —CN or —NH(CH 2 ) m CH 3 ;

R 3 is —(CH 2 ) m CH 3 or —O—(CH 2 ) m CH 3 ;

X is —H or —CH 3 ;

each n is independently 1, 2, or 3; and

each m is independently 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R is selected from the group consisting of:

3. The compound of claim 1 , wherein the compound is selected from the group consisting of:

4. A compound of Formula (I):

wherein:

R is selected from the group consisting of:

X is —H or —CH 3 ;

or a pharmaceutically acceptable salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: THE THEO GROUP
To: PEAK BIO, INC.
Reel/Frame 069263/0109 →
SECURITY INTEREST Recorded Jul 23, 2024
From: PEAK BIO, INC.
To: THE THEO GROUP
Reel/Frame 068057/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2019
From: JAMMALAMADAKA, VASU; TIPTON, KIMBERLY ANN; SATYAL, SANJEEV; HUH, HOYOUNG
To: PH PHARMA CO., LTD.
Reel/Frame 048232/0077 →
Continuity (3)
Provisional Application 62686781 · Jun 19, 2018
Provisional Application 62561060 · Sep 20, 2017
Related Publication 20190084996A1 · Mar 21, 2019